PTN
Palatin Technologies, Inc. AMEX Listed Oct 15, 1997$10.48
-0.10%
vs $10.49
Mkt Cap $18.6M
52w Low $5.61
19.2% of range
52w High $31.00
50d MA $9.51
200d MA $16.02
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-0.0x
ROE
-193.0%
P/FCF
-0.3x
RSI (14)
75.60
ATR (14)
$1.12
Beta
0.94
50d MA
$9.51
200d MA
$16.02
Avg Volume
27.0K
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Cedar Brook Corporate Center · Cranbury, NJ 08512 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | AMC | -2.35 | -2.86 | -21.5% | 17.59 | -6.5% | +10.0% | +8.5% | +7.0% | +0.1% | +2.3% | — |
| Nov 14, 2025 | AMC | — | 4.26 | — | 10.80 | +0.0% | +17.9% | +6.5% | +1.8% | +5.0% | +57.5% | — |
| Sep 23, 2025 | AMC | -9.50 | -4.14 | +56.4% | 10.06 | +1.9% | +2.9% | -1.0% | -2.0% | -37.2% | +25.5% | — |
| May 21, 2025 | AMC | -0.17 | -0.53 | -211.8% | 6.00 | -8.3% | +0.0% | -8.3% | -9.1% | +0.0% | +0.0% | — |
| Feb 13, 2025 | AMC | -0.42 | -0.12 | +71.4% | 53.00 | -1.9% | -5.7% | +3.0% | -1.9% | +1.0% | -2.0% | — |
| Oct 1, 2024 | AMC | -0.55 | -0.51 | +7.3% | 44.00 | +1.1% | -6.8% | +1.2% | +6.0% | +3.4% | -4.4% | — |
| Sep 30, 2024 | AMC | -0.56 | -0.49 | +12.5% | 44.50 | +3.4% | -1.1% | -6.8% | +1.2% | +6.0% | +3.4% | — |
| May 15, 2024 | AMC | -0.66 | -0.53 | +19.7% | 103.50 | +1.4% | -1.4% | -2.0% | +2.0% | +1.5% | -1.4% | — |
| Feb 14, 2024 | AMC | -0.43 | -0.56 | -30.2% | 207.00 | -2.7% | -23.9% | -4.1% | +7.3% | -8.0% | +7.0% | — |
| Nov 14, 2023 | AMC | -0.75 | -0.48 | +36.0% | 96.00 | +1.0% | +3.6% | -3.0% | +1.6% | -0.5% | +3.1% | — |
| Sep 28, 2023 | AMC | -0.59 | -0.91 | -54.2% | 75.00 | -3.3% | +0.7% | +13.2% | +2.3% | -1.1% | +4.6% | — |
| May 16, 2023 | AMC | -0.59 | -0.63 | -6.8% | 129.00 | +0.8% | -5.4% | +0.4% | +2.4% | -1.6% | -0.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.50 | $51.00 | +3.0% | +7.1% | -5.7% | +3.0% | -1.9% | +1.0% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $49.50 | $51.00 | +3.0% | +6.1% | -8.6% | +3.1% | +0.0% | +7.1% |
| Dec 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.50 | $37.50 | +0.0% | +14.7% | +12.8% | +0.0% | +2.1% | +12.1% |
| Nov 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $48.00 | $48.50 | +1.0% | +14.6% | -2.7% | +5.6% | +0.9% | +0.9% |
| Nov 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $60.00 | $60.00 | +0.0% | -0.8% | -1.7% | -6.8% | +6.4% | +12.1% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $63.00 | $63.50 | +0.8% | -1.6% | -3.2% | -0.8% | -1.7% | -6.8% |
| Oct 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $54.50 | $55.00 | +0.9% | +0.9% | -0.9% | +11.0% | -5.0% | +9.6% |
| Jun 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $103.50 | $104.00 | +0.5% | -9.2% | +0.5% | -3.7% | -0.5% | +0.6% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $92.50 | $95.00 | +2.7% | +6.5% | -1.5% | -6.2% | +0.0% | +13.7% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $120.50 | $110.50 | -8.3% | -14.1% | -1.4% | -2.0% | +2.0% | +1.5% |
| May 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $104.00 | $104.00 | +0.0% | -1.4% | +14.6% | -2.6% | +6.1% | -0.8% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $93.50 | $95.50 | +2.1% | +9.6% | +2.9% | -5.2% | +4.0% | -1.4% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $198.50 | $110.00 | -44.6% | -38.3% | -18.0% | +9.5% | -10.0% | -0.5% |
| Feb 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $207.00 | $201.50 | -2.7% | -23.9% | -4.1% | +7.3% | -8.0% | +7.0% |
| Aug 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $145.50 | $145.00 | -0.3% | -5.5% | +0.7% | +1.4% | -10.7% | -2.4% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.00 | $125.00 | +2.5% | +8.2% | +10.2% | -5.5% | +0.7% | +1.4% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $98.50 | $106.50 | +8.1% | +23.9% | +8.2% | +10.2% | -5.5% | +0.7% |
| May 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $122.00 | $127.50 | +4.5% | +1.6% | -1.2% | -7.3% | +2.6% | +0.9% |
| Sep 9 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $315.50 | $300.00 | -4.9% | +7.4% | +15.0% | -3.2% | -12.6% | +2.0% |
| Sep 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $315.50 | $300.00 | -4.9% | +7.4% | +15.0% | -3.2% | -12.6% | +2.0% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $425.00 | $662.50 | +55.9% | +50.0% | +9.8% | +53.6% | -17.4% | -19.7% |
| Jun 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $1125.00 | $1762.50 | +56.7% | +11.1% | +15.0% | -1.7% | +0.9% | -5.3% |
No insider trades available.
8-K
Palatin Technologies, Inc. -- 8-K Filing
Palatin Technologies' shareholders elected four directors and ratified KPMG LLP as the independent auditor for fiscal year 2026, indicating continued governance stability.
Aug 3
8-K · 7.01
! Medium
Palatin Technologies, Inc. -- 8-K 7.01: Regulation FD Disclosure
Palatin Technologies' move from NYSE to Nasdaq listing may affect stock liquidity and trading accessibility, potentially reflecting operational changes or cost optimization for the biopharmaceutical company.
May 18
Valuation
Market Cap
$18.6M
Enterprise Value
$3.1M
P/E (TTM)
—
Forward P/E
5.57x
PEG Ratio
-0.00x
P/B
—
P/S
1.45x
P/FCF
-0.26x
EV/EBITDA
—
Shares Out
538K
Financials (TTM)
Revenue
$12.9M
Net Income
-$6.2M
EBITDA
-$6.1M
Free Cash Flow
-$21.3M
Op Cash Flow
-$21.3M
EPS Basic
$-32.15
EPS Diluted
$-4.16
EPS Forward
$1.88
Gross Margin
99.8%
Op Margin
-50.6%
Net Margin
-48.5%
Balance Sheet
Total Assets
$3.3M
Total Liab.
$8.0M
Total Equity
-$4.8M
Cash
$2.6M
LT Debt
$0
Book Value/Sh
$-8.87
Debt/Equity
-0.03x
Current Ratio
0.36
Quick Ratio
0.36
Returns & Growth
ROE
-193.0%
ROA
-123.4%
ROIC
492.2%
Rev Growth YoY
-100.0%
EPS Growth YoY
-1491.6%
Price Returns
2W
+12.0%
1M
+29.7%
3M
-25.2%
6M
-49.9%
12M
+2.6%
Technicals
52W High
$31.00
52W Low
$5.61
50d MA
$9.51
200d MA
$16.02
RSI (14)
75.60
ATR (14)
$1.12
Beta
0.94
Avg Volume
27K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$55.00
High
$60.00
Low
$50.00
Median
$55.00
Data updated apr 26, 2026 9:10pm
· Source: financialmodelingprep.com